<- All drugs

BI 3034701

MARKETED

GLP-1/GIP/NPY2 receptor triple agonist (peptide)

graded findings

effect domains

Evidence spread

High evidence 0Moderate evidence 0Low evidence 0Very low evidence 3

BI 3034701 is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

BI 3034701 MARKETED

Weight change Decrease

Very low evidence

BI 3034701 (Boehringer Ingelheim / Gubra) is an investigational, potential first-in-class triple GLP-1 / GIP / NPY2 receptor agonist peptide for obesity. The phase 1...

Boehringer Ingelheim / Gubra press releases (phase 1 start 2024; phase 2 advance 2026) Source

Full findingBI 3034701 (Boehringer Ingelheim / Gubra) is an investigational, potential first-in-class triple GLP-1 / GIP / NPY2 receptor agonist peptide for obesity. The phase 1 first-in-human trial demonstrated a favourable safety/tolerability profile and showed encouraging weight loss; Boehringer plans to initiate phase 2 in mid-2026.

PopulationPhase 1 (NCT06352437): randomised first-in-human placebo-controlled, two parts - Part A healthy men 18-55; Part B adults 18-65 with overweight/obesity otherwise healthy; ~124 participants; completed H2 2025

Fundingindustry (company press release on own pipeline)

Scope limitsMECHANISM CORRECTION: a triple agonist but the third axis is NPY2 (peptide YY pathway), NOT glucagon or amylin - distinguishes it from the GIP/GLP-1/glucagon triples (retatrutide, efocipegtrutide, HM15275) and from amylin agents. Gap-filled by parent; flagged as a real triple by the amylin cluster. NCT06352437 confirmed.

Comparatorsplacebo

BI 3034701 MARKETED

Weight change Not directional

Very low evidence

No human weight-loss data reported; rationale is multi-pathway satiety/body-weight regulation.

Boehringer Ingelheim / Gubra press disclosures, 2025-2026. Source

PopulationNone (preclinical/early clinical)

Fundingindustry (company press release on own pipeline)

Scope limitsPlaceholder for an asset with verified mechanism but no efficacy readout yet. Avoid conflating with Boehringer's survodutide (glucagon/GLP-1 dual) which is a separate, more advanced program.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

BI 3034701 MARKETED

Pharmacology and mechanism Not directional

Very low evidence

Mechanism verified: investigational, potential first-in-class triple agonist at GLP-1, GIP and NPY2 (Y2) receptors, designed to engage multiple satiety pathways.

Gubra / Boehringer Ingelheim announcement: Boehringer Ingelheim advances Gubra-originated... Source

PopulationPreclinical/early development (mechanism per company/partner disclosures)

Fundingindustry - Boehringer Ingelheim (trial sponsor; inferred from registration trial)

Scope limitsMechanism confirmed as GLP-1/GIP/NPY2 triple AGONIST (note: GIP arm is agonist, unlike MariTide's GIPR antagonism). NPY2 (Y2) agonism = additional anorexigenic axis (PYY-like). No human efficacy data yet; Phase 2 planned ~mid-2026. Press-sourced; no PMID/NCT verified for this asset yet.